The book highlights important new research approaches of clinical relevance, written by prominent researchers in the field of OCD and related disorders. A broad range of topics is covered, beginning with a description of the phenotypic features of the OCD followed by chapters on developmental aspects, animal models, genetic and biological models including neuro-inflammation, functional neuroimaging correlates and information-processing accounts. Finally, existing and novel treatment approaches are covered including clinical and pharmacogenetic treatment models. In this way the volume brings together the key disciplines involved in the neurobiological understanding of OCD to provide an update of the field and outlook to the future. Together, the volume chapters provide focused and critical reviews that span a broad range of topics suitable for both students and established investigators and clinicians interested in the present state of OCD research.

This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.

The book highlights important new research approaches of clinical relevance, written by prominent researchers in the field of OCD and related disorders. A broad range of topics is covered, beginning with a description of the phenotypic features of the OCD followed by chapters on developmental aspects, animal models, genetic and biological models including neuro-inflammation, functional neuroimaging correlates and information-processing accounts. Finally, existing and novel treatment approaches are covered including clinical and pharmacogenetic treatment models. In this way the volume brings together the key disciplines involved in the neurobiological understanding of OCD to provide an update of the field and outlook to the future. Together, the volume chapters provide focused and critical reviews that span a broad range of topics suitable for both students and established investigators and clinicians interested in the present state of OCD research.

This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.

In recent years there have been major advances in areas of clinical neuroscience including neurogenetics, neuroimaging and the scientific study of consciousness. Disorders of Brain and Mind II brings together the most important findings since the previous volume was published in 1998. Imaging of the normal and abnormal mind figures prominently, and there is coverage of genes and behavior, brain development, consciousness and aggression. New disease-oriented chapters detail recent advances in dementia, affective illness and drug use and abuse. Clinical chapters are paired with those describing neuropathology or experimental models of disease.

This latest volume in the critically acclaimed and highly influential Attention and Performance series focuses on two of the fastest moving research areas in cognitive and affective neuroscience - decision making and emotional processing.
Decision Making, Affect, and Learning investigates the psychological and neural systems underlying decision making, and the relationship with reward, affect, and learning. In addition, it considers neurodevelopmental and clinical aspects of these issues - for example the role of decision making and reward in drug addiction. It also looks at the applied aspects of this knowledge to other disciplines, including the growing field of Neuroeconomics.
After an introductory chapter from the Volume editors, the book is then arranged according to the following themes:
Psychological Processes underlying decision-making.
Neural systems of decision-making
Neural systems of emotion, reward and learning
Neurodevelopmental and clinical aspects
Superbly written and edited, the book highlights the complex interplay between emotional and decision-making processes and their relationship with learning.

This book presents 13 reviews collected to present the new advances in all areas of addiction research, including knowledge gained from mapping the human genome, the improved understanding of brain pathways and functions that are stimulated by addictive drugs, experimental and clinical psychology approaches to addiction and treatment, as well as both ethical considerations and social policy. The book also includes chapters on the history of addictive substances and some personal narratives of addiction. Introduced by Sir David King, Science Advisory to the UK Government and head of the Office of Science and Technology, and Nora Volkow, director of the National Institute on Drug Abuse in the USA, the book uniquely covers the full range of disciplines which can provide insight into the future of addiction, from genetics to the humanities. Written for a scientific audience, it is also applicable to non-specialists as well.
* Provides an unique overview of what we know about addiction, and how scientific knowledge can and should be applied in the societal, ethical, and political context
* Applies the state-of-the-art research in fields such as Genomics, Neuroscience, Pharmacology, Social Policy and Ethics to addiction research
* Includes a preface by Sir David King, Science Advisory to the UK Government and head of the Office of Science and Technology, and in introduction by Nora Volkow, director of the National Institute on Drug Abuse in the USA